Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults

What Was Tested

The paper reports a study of MK-677 (Ibutamoren), published as a randomized controlled trial.

Blood was collected every 20 min for 24 h before treatment and at the end of each period for GH measurement using an ultrasensitive assay.

Who Took Part

The study group was 677 subjects.

PubMed indexes the participants as teenagers and adults.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this MK-677 (Ibutamoren) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind MK-677 (Ibutamoren) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the MK-677 (Ibutamoren) group a baseline to be compared against.

Each person switched between MK-677 (Ibutamoren) and the comparison at some point, usually with a gap in between.

A time span of 4 days appears in the methods.

What Was Measured

Blood was collected every 20 min for 24 h before treatment and at the end of each period for GH measurement using an ultrasensitive assay.

The subject headings attached to it are Blood Glucose, Circadian Rhythm, Hormones, Human Growth Hormone, Indoles, Insulin and Insulin-Like Growth Factor I.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of MK-677 (Ibutamoren) in 677 subjects over 4 days.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 1997 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the MK-677 (Ibutamoren) compound page, all human trials.